Scholtz & Company’s DexCom DXCM Stock Holding History

Scholtz & Company’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.31M	Buy	68,648 +309	+0.5%	+$21.5K	2.21%	18
2025 Q4	$4.54M	Buy	68,339 +36,392	+114%	+$2.35M	1.97%	18
2025 Q3	$2.15M	Buy	31,947 +25,261	+378%	+$2M	0.94%	36
2025 Q2	$584K	Buy	6,686 +90	+1%	+$7.05K	0.26%	40
2025 Q1	$450K	Buy	+6,596	New	+$538K	0.22%	40
2024 Q4	–	Sell	-25,527	Closed	-$1.71M	–	50
2024 Q3	$1.71M	Sell	25,527 -1,330	-5%	-$109K	0.81%	33
2024 Q2	$3.05M	Buy	26,857 +1,059	+4%	+$134K	1.3%	27
2024 Q1	$3.58M	Buy	25,798 +3,259	+14%	+$410K	1.58%	25
2023 Q4	$2.8M	Buy	+22,539	New	+$2.3M	1.38%	25

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Scholtz & Company's DXCM Position: Q1 2026 in Review

Scholtz & Company increased its DexCom (DXCM) stake by 0.45% in Q1 2026, buying an estimated $21.5K and bringing the position to 68,648 shares worth $4.31M. The position accounts for 2.21% of the portfolio, ranked #18.

Scholtz & Company first reported a position in DXCM in Q4 2023 and has held it in 9 quarters since. The position peaked at $4.54M in Q4 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Scholtz & Company held 68,648 shares of DexCom worth $4.31M as of Q1 2026.
Scholtz & Company bought 309 DexCom shares in Q1 2026, an estimated $21.5K.
DexCom made up 2.21% of Scholtz & Company's portfolio in Q1 2026, its #18 holding.
Scholtz & Company first reported a position in DexCom in Q4 2023 and has held it in 9 quarters since.
Scholtz & Company's DexCom position peaked at $4.54M in Q4 2025.
956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Scholtz & Company's 13F filing for Q1 2026, filed 15 May 2026.